Hepatic, renal, and immune system impairment are associated with chronic hepatitis C virus (HCV) infection. This study looked at how some hepatic and renal functions in HCV patients were impacted by treatment with direct acting antivirals (DAAs). Six hundred male and female Egyptian patients with HCV infection who received three months of sofosbuvir/daclatasvir combined therapy and were primarily identified by anti-HCV antibodies were prospectively enrolled. This study measured peripheral blood hematological parameters, pre- and post-treatment serum HCV RNA viral load, alpha-fetoprotein, ALT, AST, total bilirubin, creatinine, and other parameters. Three months of sofosbuvir/daclatasvir combined therapy resulted in SVR in 100% of patients. Blood hemoglobin, platelets count, neutrophils%, and eosinophil% were all significantly higher after treatment, whereas post-treatment HCV RNA viral load, alpha-fetoprotein ALT, AST, total bilirubin, creatinine, total leucocyte count, lymphocytes percent, and monocytes percent were all significantly lower. This study's findings suggest that DAAs sofosbuvir/daclatasvir combined therapy for three months has a significant impact on biochemical, immunological, and hematological parameters, suggesting clinically significant findings in patients with CHC who have been successfully treated.